Skip to main content
OpenTrials
Completed

NCT Number: NCT00932750

Study of Coffee Mannooligosaccharides for Weight Management

The goal of this study is to establish the role of coffee mannooligosaccharides (MOS), provided in a beverage format, on body weight regulation. Overweight and obese men and women will be randomized to one of 2 groups: placebo or MOS beverage. They will be required to consume 2 beverages/day for the duration of the 2 phases of the study. The MOS beverage will provide 2 g of MOS (total of 4 g/d). This dose level has been found to be well tolerated and safe. In the first phase, subjects will be counseled once monthly on a nutrition-related topic on an individual basis. They will be asked to maintain their regular eating and exercise habits for the duration of the 12 week period. An 8-week washout period will follow during which time they will not be required to consume the beverages. The second phase of the study will be a weight loss phase. For this phase, subjects will be re-randomized and may consume the alternate or the same beverage as the first phase, depending on the outcome of randomization. During this phase, they will undergo group counseling on a weekly basis. Counseling sessions will focus on weight loss and ways to achieve moderate weight loss of approximately 1-2 lbs/week. Measurements will be taken at the beginning and end of each phase. This study will allow us to determine whether MOS helps maintain body weight and prevent weight gain (first phase) and whether it helps to stimulate weight loss (second phase). The results will allow us to find ways in which overweight and obese individuals can incorporate beverages in their diets that will help promote weight loss.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

St. Luke's/Roosevelt Hospital

New York, 10025, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body mass index 27-33 kg/m2
  • Stable body weight

Exclusion criteria

  • Body width > 46 cm
  • Medications known to affect body weight, lipids, blood pressure
  • Pregnant or lactating women
  • Less than 1 y post-partum

Treatment and study plan

Coffee mannooligosaccharide

Dietary Supplement

2 beverages daily providing either 4 g of coffee mannooligosaccharide or placebo.

Coffee mannooligosaccharides

Dietary Supplement

Subjects consume 2 beverages daily providing 4 g of coffee mannooligosaccharides or placebo

Primary outcomes

  1. Body Composition by Magnetic Resonance Imaging

    Time frame: Baseline and Endpoint

  2. Blood pressure

    Time frame: Weekly

  3. Body weight

    Time frame: Weekly

  4. Waist circumference

    Time frame: Weekly

Secondary outcomes

  1. Appetite/Satiety

    Time frame: Weekly

Sponsors and collaborators

Lead sponsor

Mondelēz International, Inc.

Industry

Collaborators

  • St. Luke's-Roosevelt Hospital Center

Registry information

Official study title

THE EFFECTS OF COFFEE MANNOOLIGOSACCHARIDES ON INDICES OF BODY WEIGHT, BODY COMPOSITION, AND SATIETY IN HUMANS

Acronym: MOS

Important dates

Study start
2006
Primary completion
2007
Study completion
2007
First posted
Jul 3, 2009
Registry last updated
Aug 22, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.